Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07052266
NA

Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening

Sponsor: Weill Medical College of Cornell University

View on ClinicalTrials.gov

Summary

The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception/fertility care. The goal is to evaluate the acceptability of BRCA1/2 testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention and be cost-effective, especially among underserved populations.

Official title: Feasibility of Obstetric and Cancer Universal Screening

Key Details

Gender

FEMALE

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

550

Start Date

2025-09-02

Completion Date

2028-12

Last Updated

2025-12-26

Healthy Volunteers

No

Interventions

GENETIC

MyRisk Hereditary Cancer Test

Subjects that are planning to proceed with OCS and enrolled in the trial will be contacted by the genetics clinician (by telephone or in person, based on subject preference) to review the option for HCS in addition to OCS. The WCM genetics clinician will review the potential risks and benefits, possible findings, and implications of findings for HCS. The genetics clinician will follow WCM standards (outlined by the WCM Genetics and Personalized Cancer Prevention Program https://wcinyp.org/GPCP) for informed consent counseling on the potential risks/benefits of HCS. The counseling regarding OCS will have already been performed by the obstetrical team as part of the standard of care. The genetics clinician will review that OCS is being performed as part of the patient's standard of care prenatal visit and HCS is an additional component that is being performed as part of participation in this clinical trial.

Locations (5)

Reproductive Medicine

Brooklyn, New York, United States

NewYork-Presbyterian Weill Cornell Medicine

Brooklyn, New York, United States

Reproductive Medicine

New York, New York, United States

Weill Cornell Medicine

New York, New York, United States

NewYork-Presbyterian Weill Cornell Medicine Queens

Queens, New York, United States